A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongat...

by Mason JW, Moon TE, O’Boyle E, Dietz A
Published 2014-03-01

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

by Gabrail N, Yanagihara R, Spaczyński M, Cooper W, O’Boyle E, Smith C, Boccia R
Published 2015-03-01